A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512215-53-00

Acronym

MK-8591A-033

Enrollment

Registered

2024-07-01

Start date

2021-10-27

Completion date

Unknown

Last updated

2025-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV infection

Brief summary

Percentage of participants with serious adverse events (SAEs), Percentage of participants who discontinued study treatment due to an adverse event (AE)

Interventions

DRUGMK-8591A

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of participants with serious adverse events (SAEs), Percentage of participants who discontinued study treatment due to an adverse event (AE)	—

Countries

France, Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026